Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics Europe 2021

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology

Prof. Soper (since 2016) is a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$105M, has published over 245 peer-reviewed manuscripts (h index = 67; 16,188 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 48 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.

His major discoveries include: (1) Technology for the detection of circulating tumor cells that can manage a variety of cancer diseases using a simple blood test (test has been demonstrated in multiple myeloma, pediatric acute lymphoblastic leukemia, acute myeloid leukemia, pancreatic, breast, colorectal, prostate, and ovarian cancers); (2) new hardware and assay for the point-of-care diagnosis of acute ischemic stroke; (3) single-molecule DNA and RNA sequencing nanotechnology; and (4) currently working on a home-test for COVID-19 infections (handheld instrument and the associated assay).

Steve Soper Image

Isolation and Analysis of Liquid Biopsy Markers using Microfluidics and a Liquid Handling Robot

Monday, 28 June 2021 at 15:00

Add to Calendar ▼2021-06-28 15:00:002021-06-28 16:00:00Europe/LondonIsolation and Analysis of Liquid Biopsy Markers using Microfluidics and a Liquid Handling RobotLab-on-a-Chip and Microfluidics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Liquid biopsies are generating great interest within the medical community due to the simplicity for securing important biomarkers to manage complex diseases, such as many of the cancer-related diseases. We are developing a suite of novel microfluidic devices that can process clinical samples directly and efficiently search for a variety of disease-associated liquid biopsy markers, such as circulating tumor cells (CTCs), cell free DNA (cfDNA), and extracellular vesicles (EVs). The microfluidic chips are made in plastics via injection molding and designed to optimize recovery and purity of each of the aforementioned biomarkers. The challenge with microfluidics is the need for attaching connector tubing to the microfluidic and using syringe pumps to fluidically operate the chips. We have developed liquid handling robots to automatically operate microchips and do so in a high throughput and automated fashion, appropriate for use in centralized clinical testing laboratories. The robots operate using pipet tips and do not require connector tubing reducing chip production costs. The robotic platforms were used along with specifically designed chips for analysis of each of the liquid biopsy markers. Examples of using the system for supporting large clinical studies will be discussed, such as CTCs for discovering new therapies for pancreatic cancer, cell free DNA genotyping for breast cancer, and EVs for patient stratification in ovarian and breast cancers.


Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Europe 2021Lab-on-a-Chip and Microfluidics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com